Generated: May 23, 2017
|Title:||Laminated composite for transdermal administration of fentanyl|
|Abstract:||A laminated composite for administering fentanyl transdermally that consists of a fentanyl-impermeable occlusive backing layer and an adhesive fentanyl reservoir layer comprising fentanyl dissolved in an amine-resistant polydimethylsiloxane that has a high diffusivity and poor solubility for fentanyl which enables the fentanyl to be released rapidly from the composite over a one day period with little residual fentanyl left in the reservoir thereafter.|
|Inventor(s):||Cleary; Gary W. (San Mateo, CA), Roy; Samir D. (Redwood City, CA)|
|Assignee:||Cygnus Therapeutic Systems (Redwood City, CA)|
|Filing Date:||Jan 15, 1992|
|Claims:||1. A solid-state laminated composite for administering fentanyl transdermally comprising: |
(a) a backing layer that is substantially impermeable to fentanyl and defines the face surface of the composite,
(b) an adhesive fentanyl reservoir layer that defines the basal surface of the composite during use and comprises:
(i) 1 to 5% by weight fentanyl;
(ii) 1 to 10% by weight propylene glycol monolaurate (PGML);
(iii) 85 to 98% by weight of an amine resistant pressure sensitive adhesive polymer having a diffusivity to fentanyl in the range of 10.sup.-8 to 10.sup.-11 cm.sup.2 /sec and a solubility for fentanyl in the range of 1.5 to 5 mg/ml,
said composite exhibiting a steady state fentanyl skin flux in the range of about 2 to about 10 mcg/cm.sup.2 /hr and administering at least about 75% of the fentanyl in the composite during approximately the first day of use.
2. The laminated composite of claim 1 wherein the fentanyl comprises 1.7 to 3% be weight of the reservoir layer, the propylene glycol monolaurate comprises 1.5 to 5% by weight of the reservoir layer and the polymer comprises about 90 to 96% by weight of the reservoir layer.
3. The laminated composite of claim 1 wherein the backing layer is occlusive.
4. The laminated composite of claim 3 wherein the polymer is a polydimethylsiloxane.
5. The laminated composite of claim 3 wherein said basal surface has an area of 10 to 40 cm.sup.2, the steady state fentanyl flux is in the range of 2 to 10 mcg/cm.sup.2 /hr and at least about 85% of the fentanyl is administered during approximately the first day of use.
6. The laminated composite of claim 3 including (c) a porous structural layer interposed between the backing layer and the reservoir layer.
7. The laminated composite of claim 6 wherein the porous structural layer is made of a nonwoven fabric.
8. The laminated composite of claim 6 wherein the porous structural layer is adhered to the backing layer by a layer of said amine resistant pressure sensitive adhesive polymer composition.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.